ClinicalTrials.gg
CompletedNCT03697447Updated Aug 21, 2024

Endermotherapy With Burn Hypertrophic Scars

An interventional study of Endermotherapy in Burn Scar, sponsored by Centre hospitalier de l'Université de Montréal (CHUM). Completed at 1 site in Canada. Open to participants aged 14 Years and older. Per ClinicalTrials.gov, last updated 2024-08-21.

Sponsored by Centre hospitalier de l'Université de Montréal (CHUM) · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Registered 1 year 1 month after the study started (first participant enrolled Feb 2017, registered Mar 2018).
Phase
Not applicable
Study type
Interventional
Enrollment
19
Allocation
Randomized
Ages
14 Years and older
Sex
All
01

Study summary

Mechanical massage or endermotherapyTM is applied to scar tissue with the intended therapeutic value being the promotion of structural or physiological changes. These proposed changes are meant to induce more pliability, so that skin possesses the strength and elasticity required for normal mobility. The advantage of mechanical massage compared to manual massage is that it provides a standard dosage using rollers and suction valves to mobilize the tissue. However, research documenting and supporting this effect is lacking. The objective of this proposal is to document the effect of 12 weeks of endermotherapy treatment on hypertrophic scar characteristics, including erythema, pigmentation, pliability, and thickness in adult burn survivors and their subjective evaluation of itch, pain and overall scar outcome through a prospective, randomized, controlled, within-patient, single-blinded study.

Read the detailed description

Patients will receive 12 weeks of endermotherapy , 3 times a week.

02

Conditions studied

  • Burn Scar
03

In context

Lead sponsor

Centre hospitalier de l'Université de Montréal (CHUM) is the lead sponsor of 376 studies on the registry; 110 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
14 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • females and males, of any race, 14 years or older,
  • a thermal injury,
  • at least 3 months post-burn so that the scars will be durable enough to tolerate the proposed forces,
  • at least 2 scar sites >2.034 mm thick and within 0.5 mm of each other, and
  • signed the informed patient consent form

Exclusion criteria

Exclusion Criteria:

  • subjects who have keloids,
  • with a diagnosis of psychiatric illness clearly documented in their medical file,
  • mechanism of injury is an electrical, chemical, or cold injury,
  • a dermatological conditions in the region of the evaluation site, that may interfere with the study results,
  • a suspected or known allergy to ultrasound gel,
  • unable to understand French or English, or
  • subjects who refuse to give informed consent.
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Investigator, Outcomes assessor)
Enrollment
19 participants (actual)

Study arms

  • Experimental
    Endermotherapy treated scar

    Endermotherapy massage treatment

    Procedure: Endermotherapy

  • No intervention
    Control scar

    No intervention, standard of care

Interventions

  • ProcedureEndermotherapy

    Endermotherapy massage (mechanic massage) of burn scar

06

What researchers measure

Primary outcomes

  1. Skin Thickness Changes

    Ultrasound skin measures, mm

    Time frame: baseline, 12, 24 and 36 weeks

Secondary outcomes

  1. Cutometer Skin Elasticity Changes

    skin elasticity measures (r0- cutometer), mm

    Time frame: baseline, 12, 24 and 36 weeks

  2. Mexameter Skin Erythema Changes

    Erythema index measure by Mexameter, scale values of 0 to 999. The erythema values are individual for each person and depend strongly on the ethnic group. The measurements are generally used to determine changes before and after a treatment.

    Time frame: baseline, 12, 24 and 36 weeks

  3. Itch Visual Analog Subjective Changes

    Itch, Visual analog scale (score 0-none to 10-worse)

    Time frame: baseline, 12, 24 and 36 weeks

  4. Pain Visual Analog Subjective Changes: VAS

    Pain, Visual analog scale (score 0-none to 10-worse)

    Time frame: baseline, 12, 24 and 36 weeks

07

Study locations

1 site
  • Montreal Burn Unit
    Montreal, Quebec H2X 1C9, Canada
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Feb 2017 to primary completion in Feb 2020, 35 months.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 22, 2018
First posted
Oct 5, 2018
StartActual
Feb 13, 2017
Primary completionActual
Feb 5, 2020
CompletionActual
Feb 5, 2020
Last update
Aug 21, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 21, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03697447
Responsible party
Sponsor
First posted
Oct 5, 2018
Start date
Feb 13, 2017
Primary completion
Feb 5, 2020
Completion
Feb 5, 2020
Last update
Aug 21, 2024

Study contacts

Bernadette Nedelec, PhD
principal investigator · CRCHUM

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion